TriSalus Life Sciences Inc. (Nasdaq: TLSI), a company focused on improving outcomes for patients with solid tumors, has announced the successful completion of its exchange offer and consent solicitation for its Series A Convertible Preferred Stock. The offer, which allowed holders to exchange each preferred share for 3.3 shares of common stock, expired on July 23, 2025. Approximately 98.82% of the outstanding Preferred Stock was tendered, and the company expects to finalize the exchange and settlement by August 1, 2025. This move marks a significant step in the company's financial restructuring efforts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.